Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
Vall d'Hebron Institute of Oncology
BioEclipse Therapeutics
Sheba Medical Center